1383TiPBlood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC
Mok, T.S.K., Gadgeel, S., Kim, E.S., Velcheti, V., Hu, S., Riehl, T., Schleifman, E., Paul, S.M., Mocci, S., Shames, D.S., Phan, S., Yun, C., Mathisen, M., Kowanetz, M., Sweere, U., Socinski, M.A.Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx380.084
Date:
September, 2017
File:
PDF, 71 KB
english, 2017